May 16, 2019TOLREMO is a 2019 »venture» finalist TOLREMO therapeutics is one of the top 10 finalists in the “Health & Nutrition” vertical of this year’s »venture» business plan competition. »venture» is Switzerland’s leading startup contest for entrepreneurs with innovative business ideas – with workshops, coaching and networking opportunities »venture» provides the essential environment to turn the participant’s ideas into reality.

May 3, 2019TOLREMO on stage at the Swiss Biotech Day 2019 (7.5.2019 at Congress Center in Basel)Great news on the TOLREMO front: We are thrilled to be part of this year’s Swiss Biotech Day. Our CEO Stefanie Flückiger-Mangual gets the chance to present TOLREMO at this vivid annual get-together of the Swiss biopharmaceutical industry. Be kindly invited to join our afternoon talk in Room Montreal starting at 1.30pm.

April 4, 2019TOLREMO is one of the Bilan ‘Top 50 Startups in Which to Invest 2019’The business magazine Bilan nominated TOLREMO therapeutics as one of the top 50 Swiss startups in which to invest in 2019. In a ceremonious event that took place at the Hotel Savoy in Lausanne, TOLREMO was selected as one of 4 companies in the Biotech category.

March 11, 2019Labiotech.eu Interview – How to Make Cancer Drug Resistance FutileFor many solid tumors, treatments undergo a cycle: the drugs initially work well, the tumor shrinks, but then becomes resistant again. Stefanie Flückiger-Mangual, CEO of the Swiss biotech TOLREMO, believes that this cycle can be stopped.

February 21, 2019Stefanie Flückiger-Mangual in Swiss Venture Capital Report 2019 The Swiss Venture Capital Report is the reference publication for investments in Swiss start-ups. TOLREMO’s rapid value generation and highly successful fundraising rounds make the company stand out in the ecosystem. In the ‘faces behind the figures’ section, our CEO Stefanie Flückiger-Mangual talks about TOLREMO and it’s rapid progression.

December 20, 2018Biotech Showcase 2019 (Hilton San Francisco Union Square) We are delighted to announce that TOLREMO has been chosen to present at Biotech showcase 2019 in San Francisco. Our foreseen presentation time slot is as follows:

We cordially invite you to join our session and look forward to meeting you there!

October 31, 2018Meet us @ Bio Europe 2018 in CopenhagenThe 24th Annual International Partnering Conference takes place from November 5th to 7th in beautiful Copenhagen. TOLREMO therapeutics will be present to meet with industry partners, expand business contacts and to gain insight into latest industry trends – feel free to get in touch (info@tolremo.com). See you soon at the Bella Center in Copenhagen!

September 5, 2018TOLREMO is one of the TOP 5 most promising Swiss Biotech Startups in 2018 TOLREMO therapeutics has made it directly into this year’s Top 5 Biotech Startups in Switzerland! Ranked 31st in the nation-wide rating, TOLREMO proudly takes its place as of the best 100 Swiss start-ups in the prosperous Swiss Startup ecosystem. Many thanks to all investors and experts who believe in our potential and made this outstanding achievement possible! To the article

August 30, 2018Female Founders – Von der Idee zum Erfolg Dr. Stefanie Flückiger-Mangual, CEO & Co-founder of TOLREMO therapeutics, was invited to share her industry insights and experiences as female founder of a rapidly growing biotechnology company. Together with other entrepreneurs, the panel discussed the growing role of women in a predominantly men-dominated business and investor environment. The event was covered by the Swiss Startup News channel startupticker.ch.-> To the startupticker.ch article-> Download review pdf

May 17, 2018BioCentury – TOLREMO one of Europe’s top academic spinouts

By Lauren MartzTOLREMO therapeutics was covered by BioCentury Innovations. In ‘Europe’s Piece of the Pie’ TOLREMO was named one of Europe’s top academic spinouts with disclosed financing. -> Read the full article here (pdf)

By Cormac SheridanDUBLIN – For too many cancer patients, therapy still means no more than prolonging the inevitable. Cancer drug developers are proud to trot out numbers detailing objective response rates to novel drug candidates, along with progression-free survival and overall survival data. They're not shy about charging high prices for their product offerings either. But the grim reality is that five-year survival rates for many cancers – including lung, liver and esophageal – are still well below 50 percent, even if cancer death rates continue to decline in the U.S. and other high-income countries.-> Read the article